What is the potential for developing disease specific gene therapies?

Ark Therapeutics, Ark, gene therapy, John Martin, regulator, stem cell

Are you keen to understand why many believe gene therapy has a more secure future than stem cell therapy?

At the recent 2012 World Gene Therapy Congress, part of the 7th annual World Stem Cells and Regenerative Medicine, Prof John Martin, CSO of Ark Therapeutics identified the thinking behind this idea.

He then went onto explore why the route to the market, via the regulator, is through tested technology, and also to explore the reasons why the renaissance of gene therapy will involve local delivery.

DOWNLOAD the complete presentation to make sure you have all the details!

Do you want to find out more? Take a look at some similar articles below:

How to use stem cells for functional analysis and target discovery

Released: Post Event Report from 2012 World Stem Cells & Regenerative Medicine Congress

How to grow your business within the stem cell and regenerative medicine industry

For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D

Leave a Reply

Your email address will not be published. Required fields are marked *